)
Exelixis (EXEL) investor relations material
Exelixis Jefferies Global Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Strategic transition and execution
Transitioning from a CABO-centered business toward multiple products and franchises, with Zanza development, commercial execution, early pipeline progress and disciplined expense management as priorities.
Long-term goal: build a business with multiple products and labels across RCC, NET and CRC, extending the franchise-building approach used with CABO.
CABO revenue and the planned Zanza launch support investment across internal R&D, external opportunities and share buybacks; these priorities are not viewed as mutually exclusive.
Capital allocation and R&D priorities
Annual R&D budget targeted at a cap of ~ $1B; plan is to keep expenses flat as revenue grows, supporting earnings growth and investment flexibility.
Programs are prioritized by evidence, biology, vision and commercial opportunity; franchises are assessed for potential to lead across multiple products and indications.
Financial flexibility also leaves room to pursue external opportunities when attractive, while maintaining deliberate expense management.
Zanza development and differentiation
Zanza was designed to retain CABO-like kinase activity while using a shorter half-life to make dose holds, reductions and symptom resolution more manageable, particularly in combination regimens.
Differing tissue distribution may reduce hand-foot syndrome burden; the profile supports evaluating activity and combinations across tumor types in wave one and wave two.
Seven pivotal studies are underway; management said randomized survival trials are needed to determine whether early efficacy signals translate into survival benefit.
Zanza studies are designed individually around dose, combination and patient population; efficacy, safety and secondary endpoints all influence commercial adoption.
- Zanzalintinib expansion and a 1Q RCC readout anchor the next growth phase.EXEL
UBS Global Biopharma Conference 2026 - Zanzalintinib’s 2027 milestones anchor a broader, multi-franchise growth strategy.EXEL
Stifel 2026 Healthcare Conference 2026 - CABO growth funds a broad zanza pipeline while R&D, BD and buybacks remain concurrent priorities.EXEL
3rd Annual Guggenheim Healthcare Innovation Conference - Revenue rose 10% as cabozantinib grew and zanzalintinib advanced; CRC review targets 2027.EXEL
Q3 2026 - Zanzalintinib’s pivotal pipeline and CRC launch plans anchor a multi-franchise growth strategy.EXEL
Morgan Stanley 24th Annual Global Healthcare Conference - Q4 revenue rose 13% as CABOMETYX expansion and pipeline growth shaped 2024 priorities.EXEL
Q4 2023 - CABOMETYX and zanzalintinib drive growth across oncology franchises, with AI boosting efficiency.EXEL
Citigroup’s Biopharma Back to School Summit 2026 - CABO and zanza drive growth, with immediate CRC launch readiness and robust pipeline plans.EXEL
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue rose 11% to $629M, with strong cabozantinib sales and zanzalintinib NDA review.EXEL
Q2 2026
)
)
)
)
)
)
)
)